Victory Capital Management’s Ascendis Pharma ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.5M Buy
32,912
+5,372
+20% +$1.36M ﹤0.01% 1245
2026
Q2
$7.35M Sell
27,540
-3,230
-10% -$755K ﹤0.01% 1246
2026
Q1
$7.04M Sell
30,770
-12,420
-29% -$2.78M ﹤0.01% 1204
2025
Q4
$9.21M Sell
43,190
-165,741
-79% -$34.2M 0.01% 1085
2025
Q3
$41.5M Sell
208,931
-10,187
-5% -$1.9M 0.02% 631
2025
Q2
$37.8M Buy
219,118
+94,192
+75% +$15.3M 0.02% 650
2025
Q1
$19.5M Sell
124,926
-6,427
-5% -$918K 0.02% 819
2024
Q4
$18.1M Sell
131,353
-2,505
-2% -$329K 0.02% 886
2024
Q3
$20M Sell
133,858
-551
-0.4% -$74.4K 0.02% 847
2024
Q2
$18.3M Sell
134,409
-155
-0.1% -$21.1K 0.02% 841
2024
Q1
$20.3M Buy
+134,564
New +$19.2M 0.02% 813
2021
Q2
– Sell
-518,396
Closed -$66.8M – 2745
2021
Q1
$66.8M Buy
518,396
+10,638
+2% +$1.62M 0.07% 422
2020
Q4
$84.7M Buy
507,758
+142,341
+39% +$23.5M 0.09% 319
2020
Q3
$56.4M Sell
365,417
-33,021
-8% -$4.75M 0.07% 424
2020
Q2
$58.9M Sell
398,438
-3,088
-0.8% -$424K 0.08% 369
2020
Q1
$45.2M Sell
401,526
-143,439
-26% -$18.6M 0.08% 372
2019
Q4
$75.8M Buy
544,965
+106,451
+24% +$11.8M 0.09% 315
2019
Q3
$42.2M Buy
438,514
+97,606
+29% +$10.9M 0.05% 515
2019
Q2
$39.3M Buy
340,908
+18,190
+6% +$2.18M 0.08% 387
2019
Q1
$38M Buy
322,718
+299,400
+1,284% +$26.2M 0.09% 366
2018
Q4
$1.46M Sell
23,318
-420
-2% -$26.4K ﹤0.01% 1115
2018
Q3
$1.68M Sell
23,738
-1,240
-5% -$85.4K ﹤0.01% 1136
2018
Q2
$1.66M Sell
24,978
-1,360
-5% -$89.4K ﹤0.01% 1116
2018
Q1
$1.72M Buy
26,338
+8,970
+52% +$504K ﹤0.01% 1108
2017
Q4
$696K Buy
17,368
+12,010
+224% +$437K ﹤0.01% 1288
2017
Q3
$194K Buy
+5,358
New +$154K ﹤0.01% 1541
2017
Q2
– Sell
-5,158
Closed -$144K – 1809
2017
Q1
$144K Buy
+5,158
New +$130K ﹤0.01% 1521

Other funds holding ASND

Victory Capital Management's ASND Position: Q3 2026 in Review

Victory Capital Management increased its Ascendis Pharma (ASND) stake by 20% in Q3 2026, buying an estimated $1.36M and bringing the position to 32,912 shares worth $7.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

Victory Capital Management first reported a position in ASND in Q1 2017 and has held it in 27 quarters since. The position peaked at $84.7M in Q4 2020. 346 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

  • Victory Capital Management held 32,912 shares of Ascendis Pharma worth $7.5M as of Q3 2026.
  • Victory Capital Management bought 5,372 Ascendis Pharma shares in Q3 2026, an estimated $1.36M.
  • Ascendis Pharma made up ﹤0.01% of Victory Capital Management's portfolio in Q3 2026, its #1245 holding.
  • Victory Capital Management first reported a position in Ascendis Pharma in Q1 2017 and has held it in 27 quarters since.
  • Victory Capital Management's Ascendis Pharma position peaked at $84.7M in Q4 2020.
  • 346 funds tracked by Wall St. Rank held Ascendis Pharma as of Q3 2026.

Based on Victory Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.